This work addresses the fabrication of an efficient, novel, and economically viable immunosensing armamentarium that will detect the carcinoembryonic antigen (CEA) typically associated with solid tumors (sarcomas, carcinomas, and lymphomas) and is used as a clinical tumor marker for all these malignancies. This evidence concerns the gene CEACAM5 and neoplasm.